Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33525545 | 0.97 | HPGD (0.43) | HSD17B10HPGDOPRK1EPHX1CHRM2 | |
| SCHEMBL31085636 | 0.88 | HSD17B10 (0.36) | HSD17B10HPGDOPRK1EPHX1CHRM2 | |
| SCHEMBL31208605 | 0.88 | HSD17B10 (0.36) | HSD17B10HPGDOPRK1EPHX1CHRM2 | |
| SCHEMBL31085807 | 0.88 | HSD17B10 (0.36) | HSD17B10HPGDOPRK1EPHX1CHRM2 | |
| SCHEMBL31085624 | 0.88 | HSD17B10 (0.36) | HSD17B10HPGDOPRK1EPHX1CHRM2 | |
| SCHEMBL24700253 | 0.88 | HSD17B10 (0.45) | HSD17B10HPGDOPRK1EPHX1SMN1; SMN2 | |
| SCHEMBL31208855 | 0.87 | USP2 (0.50) | HSD17B10HPGDOPRK1CHRM2CHRM1 | |
| SCHEMBL33527004 | 0.85 | HSD17B10 (0.38) | HSD17B10HPGDOPRK1EPHX1CHRM2 | |
| SCHEMBL33525498 | 0.85 | HSD17B10 (0.38) | HSD17B10HPGDOPRK1EPHX1CHRM2 | |
| SCHEMBL31209419 | 0.84 | HRH3 (0.45) | HSD17B10HPGDOPRK1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | ELI LILLY AND COMPANY (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260092075-A1 | KRAS INHIBITORS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | KRAS, NRAS, HRAS | HSD17B10 3639/4885HPGD 3490/4885OPRK1 1587/4885 |
| US-20260092075-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | HSD17B10 3739/4885HPGD 3192/4885OPRK1 1838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.